Prenumeration
Beskrivning
| Land | Finland |
|---|---|
| Lista | Small Cap Helsinki |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Nightingale Health Plc
Stock exchange release
18 March 2025 at 11:30 a.m. EET
Nasdaq Helsinki Ltd ("Nasdaq Helsinki") has today approved the listing application of Nightingale Health Plc ("Nightingale Health" or the "Company") to admit the Company's Series B shares (the "Shares") to trading on the Main Market of Nasdaq Helsinki. Trading in the Shares commences on the Main Market of Nasdaq Helsinki on 19 March 2025, with the trading code HEALTH. The total number of Shares to be admitted to trading is 40,302,841 Shares.
Nightingale Health will transfer to the Main Market of Nasdaq Helsinki from First North Growth Market Finland marketplace maintained by Nasdaq Helsinki, on which the Shares will be traded until 18 March 2025.
For further information, please contact:
Teemu Suna, CEO
ir@nightingalehealth.com
Certified Adviser
Oaklins Finland Ltd, tel. +358 9 6129 670
About Nightingale Health
Nightingale Health has developed the world's most advanced health check. Our solution provides risk detection for multiple chronic diseases from a single blood sample. Nightingale Health Check can be scaled to entire populations and it can replace many of the current routine disease risk assessments and health screening programs for chronic diseases. Detecting disease risks comprehensively and efficiently allows effective targeting and tracking of health interventions, and better prevention of chronic diseases. Nightingale Health's mission is to build sustainable healthcare and reduce health inequalities. With every sample we help to create a healthier world.
Nightingale Health operates globally with a parent company in Finland and eight subsidiaries in countries such as Japan, the United States, Singapore, and the United Kingdom. Nightingale Health has customers in more than 34 countries in the healthcare and medical research sectors. The Company's technology is being used in many of the world's leading health initiatives, such as the UK Biobank, and over 600 peer-reviewed publications validate the technology. Read more: https://nightingalehealth.com/